Gagnon Securities LLC Has $6.06 Million Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Gagnon Securities LLC grew its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 4.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 321,743 shares of the company’s stock after purchasing an additional 14,800 shares during the period. Pacira BioSciences makes up approximately 1.2% of Gagnon Securities LLC’s holdings, making the stock its 26th largest holding. Gagnon Securities LLC owned approximately 0.70% of Pacira BioSciences worth $6,062,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Pacer Advisors Inc. grew its position in Pacira BioSciences by 129.4% during the 3rd quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock worth $74,681,000 after acquiring an additional 2,799,434 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Pacira BioSciences by 314.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 553,114 shares of the company’s stock worth $8,324,000 after buying an additional 419,656 shares during the period. BNP Paribas Financial Markets raised its stake in Pacira BioSciences by 269.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock worth $5,955,000 after buying an additional 288,662 shares during the period. PDT Partners LLC bought a new position in Pacira BioSciences during the 3rd quarter worth about $3,469,000. Finally, Empowered Funds LLC bought a new position in Pacira BioSciences during the 3rd quarter worth about $3,286,000. 99.73% of the stock is currently owned by institutional investors.

Pacira BioSciences Stock Performance

Shares of Pacira BioSciences stock opened at $26.33 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $34.01. The company’s fifty day moving average is $20.06 and its 200 day moving average is $17.69.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Royal Bank of Canada reiterated a “sector perform” rating and set a $18.00 target price on shares of Pacira BioSciences in a report on Tuesday, January 14th. HC Wainwright reiterated a “buy” rating and set a $39.00 price target on shares of Pacira BioSciences in a report on Wednesday, December 4th. Needham & Company LLC raised their price objective on shares of Pacira BioSciences from $22.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Truist Financial upgraded shares of Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their price target for the company from $8.00 to $25.00 in a research report on Thursday. Finally, Barclays dropped their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 12th. One analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Pacira BioSciences presently has an average rating of “Hold” and a consensus target price of $26.20.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.